N

National Institute of Neurological Disorders and Stroke (NINDS)

390 employees

National Institute of Neurological Disorders and Stroke is a Medical trial health authority.

Investor insights

Sectors invested in

Biotechnology27
Health Care15
Medical11
Therapeutics11
Pharmaceutical11
Life Science9
Neuroscience7
Drug Discovery7
Medical Device6
Gene Therapy5
Health Diagnostics4
Biopharma3
Neuroregeneration3
Neuromodulation3
Neuroprotection3
Protein Degradation3
Neurofibromatosis3
Transcriptional Regulation3
Orphan Disease3
ALS3

Funding rounds participated in

$2.3M sweet spot round size

Most of their 38 investments are in rounds between $385K and $3.3M

Basic info

Industry

research services

Sectors

Association
Health Care
Non Profit
Medical

Date founded

1950

Investments made

n

neuro42 raised $5M on September 28, 2023

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

O

Opsin Biotherapeutics, Inc. raised $328K on July 27, 2023

Investors: National Institutes of Health and National Institute of Neurological Disorders and Stroke (NINDS)

U

UNandUP raised $3.1M on July 17, 2023

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

N

Neurexis Therapeutics raised $900K on April 19, 2023

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

N

NuvOx Pharma raised $900K on April 17, 2023

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

E

Evon Medics, LLC raised $2.9M on September 27, 2022

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

A

AXONIS Therapeutics raised $336K on September 24, 2022

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

I

Infixion Bioscience, Inc. raised undisclosed on September 20, 2022

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

A

Alume Biosciences raised $3.4M on September 9, 2022

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

A

ArunA Biomedical, Inc. raised undisclosed on May 31, 2022

Investors: National Institute of Neurological Disorders and Stroke (NINDS)

FAQ